Efgartigimod demonstrated superior efficacy over IVIG in improving MG-ADL and QMG scores in myasthenia gravis patients. Patients treated with efgartigimod experienced faster symptom improvement and ...

February 9, 2010 — Low-dose intravenous immunoglobulin (IVIG) reduces pain and improves autonomic limb symptoms in patients with long-standing, refractory complex regional pain syndrome (CRPS), a ...

AIC, a division of AIS Healthcare, now offers YIMMUGO®, manufactured by Kedrion Biopharma, for the treatment of primary humoral immunodeficiency in patients 2 years of age and older.

"[O]ur study, which has the largest cohort to date, did not show an increased rate of VTEs in patients with DM on IVIG. Therefore, it is safe to start patients on this medicine as it is one of our ...

In patients with myasthenia gravis who are being initiated on eculizumab therapy because their disease is refractory to standard treatments, the safety of an abbreviated washout period in ...

With use of intravenous immune globulin (IVIg) for the treatment of adults with dermatomyositis, a significantly higher percentage of patients experienced at least minimal improvement in disease ...

Preterm newborns are susceptible of invasion by microorganisms due to immaturity of their immune system. This study aimed at assessing the effect of IV immunoglobulins as supportive treatment in ...

Immune Thrombocytopenia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the ...

Transparency Market Research (TMR) (www.transparencymarketresearch.com) has published a new report titled, “Intravenous Immunoglobulin Market – Global Industry Analysis, Size, Share, Growth, Trends, ...